Register for April 6, 2018 Webinar


Friday, April 6, 2018, 2:00 PM - 3:00 PM EDT 

Program Description 

Duchenne Muscular Dystrophy and Formulary Decision-Making Strategies 

Duchenne muscular dystrophy (DMD) is an x-linked genetic disease caused by mutations in the DMD gene that result in the lack of production of the dystrophin protein. The dystrophin protein works to protect muscles from contraction-induced injury. Without dystrophin, children are typically diagnosed with progressive muscle weakness by age 3-6 because they have frequent falling, difficulties in rising from the floor, or experience difficulties in walking and running and may waddle when walking. Most have enlarged calves due to fat accumulation within the muscle. Muscle disease progresses throughout life resulting in loss of ambulation around age 12 and the need for ventilator support by late teen years and often death in the 20’s. With multisystem supportive care, patient lifespan has increased substantially. Currently available treatments can slow the progression of DMD but are not curative. Recently approved and in the pipeline therapies aim to correct and restore dystrophin production, and may further improve patient outcomes and quality of life.

This webinar will aim to provide a stronger understanding of DMD and current care standards, data on the emerging DMD treatments, and an understanding of how these new treatment options may increase a patient’s quality of life and affect formulary decision-making.

Learning Objectives 

At the completion of this activity, participants should be able to:

  1. Explain the pathophysiology, incidence, and life expectancy for patients with Duchenne muscular dystrophy (DMD).
  2. Discuss the current recommended care options for DMD patients, including the role of newly approved medications.
  3. Detail the impact of DMD on a patient’s quality of life and how currently available treatment affects direct and indirect costs of care.
  4. Identify at least two DMD drugs in the treatment pipeline, how these may increase patient quality of life, and where these may fit into current guidelines.
  5. Describe factors that could be used for determining formulary placement of DMD drug options.

Target Audience 

This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings.

Faculty Presenters  

Susan Downard, RPh, BSPharm
Director, Clinical Pharmacy and Drug Utilization Management
Tufts Health Plan
Watertown, Massachusetts


Stanley F. Nelson, MD
Professor, Departments of Human Genetics and Pediatrics
Co-Director, Center for Duchenne Muscular Dystrophy
Director, UCLA Certified Duchenne Care Center
David Geffen School of Medicine at UCLA
Los Angeles, California


Ruby M. Singh, PharmD, BCPS
Vice President, Education and Training
Academy of Managed Care Pharmacy
Alexandria, Virginia

2:00 pm to 2:05 pm        Welcome and Introductions
Ruby M. Singh, PharmD, BCPS 
2:05 pm to 2:30 pm   DMD Overview and Therapeutic Options
Stanley F. Nelson, MD 
2:30 pm to 2:50 pm   Formulary Management Strategies for DMD
Susan Downard, RPh, BSPharm 
2:50 pm to 3:00 pm   Audience Q&A
Ruby M. Singh, PharmD, BCPS

ACPE UAN #: 0233-0000-18-003-L01-P

Credit: 1.0 contact hours (0.1 CEU)

Activity Type: Knowledge-based

Activity Fee: There is no fee to participate in this activity.

 ACPE LogoThe Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

As an ACPE-accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of CPE activities. It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.

 AMCP Logo 

Earning CPE Credit 

To earn continuing pharmacy education (CPE) credit for this program, you must attend the entire session and participate in the pre- and post-test questions. Once completed, go to to claim CPE credit. In the enrollment code redemption area, enter the enrollment code provided during the session. Complete the program evaluation and enter your NABP ID and date of birth (MMDD). Please allow 72 hours for processing and posting in your NABP account. All CPE credit for this webinar activity must be completed no later than 5:00 PM EDT on Monday, May 7, 2018. No exceptions can be made after this date.

Statement of Commercial Support 

This educational activity is supported by an unrestricted educational grant from Sarepta Therapeutics.


This continuing education activity is provided at no cost to participants, but space is limited to the first 500 participants that join the webinar.

System Technical Requirements/Viewing Requirements  

For all activities, you should have a basic comfort level using a computer and navigating websites.

The live webinar is delivered through GoToWebinar. To view minimum technical and system requirements for the webinar, please use your web browser to check your system requirements by clicking here. Space is limited to the first 500 participants that join the webinar.

The handout will be delivered via Acrobat PDF.

CPE credit will be claimed through AMCP Learn. View the minimum technical and system requirements for continuing education online learning activities by clicking here.